The content on this site is intended for healthcare professionals only
Dr Zev Wainberg speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.
He outlines the background, and study design for this phase I/II trial, which investigated first-line liposomal irinotecan irinotecan plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in patients with pancreatic ductal adenocarcinoma.
Dr Wainberg states that a safe and tolerable dose for this regimen was established, with compelling efficacy. For this regimen, progression-free survival of 9.5 months, and a median overall survival of 12.5 months was achieved in this patient population.
He also explains the toxicity profile and the next steps for this study - which includes the launch of a the phase III NAPOLI-3 trial.
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durable responses in aRCC, how do we optimise treatment?
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma
